Palisade Bio, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting a net loss of $34,797 thousand for the nine months ended September 30, 2026.

Key Highlights

  • Net loss of $14,623 thousand for the three months ended September 30, 2026, compared to a net loss of $2,868 thousand in the same period of 2025, according to the filing.
  • Nine-month net loss of $34,797 thousand for the period ended September 30, 2026, versus $7,882 thousand for the nine months ended September 30, 2025.
  • Cash and cash equivalents of $113,613 thousand as of September 30, 2026, down from $133,385 thousand at December 31, 2025.
  • Research and development expenses of $24,376 thousand for the nine months ended September 30, 2026, compared to $4,019 thousand in the prior-year period.
  • Accumulated deficit of $187,522 thousand as of September 30, 2026, up from $152,725 thousand at December 31, 2025.
  • 179,277,820 shares of common stock outstanding as of November 6, 2026, with an additional 37,814,754 shares issuable upon exercise of pre-funded warrants at $0.0001 per share.
  • License revenue of $500 thousand recognized in the nine months ended September 30, 2026, with no license revenue in the comparable prior-year period.

Palisade Bio's Financial Position and Operating Results for the Nine Months Ended September 30, 2026

According to the filing, Palisade Bio, Inc. (NASDAQ:PALI) reported total operating expenses of $38,646 thousand for the nine months ended September 30, 2026, compared to $8,075 thousand in the nine months ended September 30, 2025. Research and development expenses drove the majority of this increase, rising to $24,376 thousand from $4,019 thousand in the prior-year period. General and administrative expenses also increased, reaching $14,270 thousand for the nine months ended September 30, 2026, versus $4,056 thousand a year earlier.

The company disclosed total other income, net, of $3,349 thousand for the nine months ended September 30, 2026, primarily from other income, net, of $3,350 thousand, partially offset by interest expense of $1 thousand. For the three months ended September 30, 2026, other income, net, was $1,077 thousand. The basic and diluted net loss per common share was $0.07 for the three months ended September 30, 2026, and $0.16 for the nine-month period, based on weighted average shares of 212,027,787 and 211,035,838, respectively.

As of September 30, 2026, the filing reported total assets of $118,545 thousand and total stockholders' equity of $112,440 thousand, compared to total assets of $134,344 thousand and total stockholders' equity of $129,380 thousand at December 31, 2025. During the nine months ended September 30, 2026, the company issued common stock in connection with a stock purchase agreement, net of issuance costs of $28 thousand, raising $2,972 thousand, and also issued 364,130 shares in connection with a Crohn's and Colitis Foundation Agreement for $563 thousand. Stock-based compensation expense and related charges totaled $14,147 thousand for the nine-month period.

What Was Disclosed

Palisade Bio filed its quarterly report for the period ended September 30, 2026, disclosing a nine-month net loss of $34,797 thousand, cash of $113,613 thousand, significantly higher operating expenses compared to the prior year, and 174,442,971 shares of common stock issued and outstanding at the balance sheet date.